News

Under the terms of the agreement, Nitten is responsible for securing regulatory approval and has exclusive rights to commercialize AzaSite for ocular bacterial infection in Japan and Taiwan.

DiaMedica, a drug discovery and development company, has reported top-line results of a proof-of-concept Phase IIa trial for DM-99, the company’s third drug in clinical development for type

HemaQuest Pharmaceuticals, a biopharmaceutical company, has received two orphan medicinal product designations from the European Commission for its product HQK-1001 for the treatment of sickle cell disease and

Acacia Pharma, a UK-based pharmaceutical company, has initiated a Phase IIa study of its product APD209 to treat cachexia in cancer patients. According to Acacia, APD209 has been

Alliance HealthCard, a provider of health discount and lifestyle benefits, has completed its acquisition of Access Plans USA. Access Plans markets health insurance and develops and distributes consumer-driven

Genzyme, a biotechnology company, has entered into an agreement to acquire the worldwide rights to Campath from Bayer HealthCare, giving Genzyme primary responsibility for the development and commercialization

Biolase Technology, a dental laser company, and National Laser Technology have reached a final settlement agreement resolving the claims and counterclaims in the lawsuit between NLT and Biolase

Shire has previously inked a deal with Glaxosmithkline (GSK) to co-promote Vyvanse, Shire’s new drug for the treatment of attention deficit and hyperactivity disorder. The agreement is expected

According to reports, Sanofi has approached Solvac, the family-owned holding vehicle that controls 30% of Solvay, and made an offer of E7.2 billion or E85 per share for